Get the Stockscreener App
8.49
4.94%
0.40
After Hours:
8.52
0.03
+0.35%
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Wolf Haldenstein Adler Freeman & Herz LLP announces that it - GlobeNewswire
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws - GlobeNewswire Inc.
(ATRA) Investment Analysis - Stock Traders Daily
2025-01-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out - Markets Insider
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out - Markets Insider
Atara stock holds Neutral rating after workforce cut - Investing.com India
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - The Malaysian Reserve
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect - Markets Insider
Atara reduction in workforce to impact 50% of current employees - MSN
2025-01-27 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect | NDAQ:ATRA | Press Release - Stockhouse Publishing
Atara Biotherapeutics Sees Its Share Price Fall - San Fernando Valley Business Journal
Atara to cut 50% of workforce amid FDA woes - MSN
Atara to cut 50% of workforce amid FDA woes (ATRA:NASDAQ) - Seeking Alpha
Atara Biotherapeutics’ (ATRA) “Neutral” Rating Reiterated at HC Wainwright - Defense World
What is HC Wainwright’s Forecast for ATRA FY2024 Earnings? - Defense World
Stifel cuts Atara Biotherapeutics target to $5, holds rating - MSN
Atara Biotherapeutics (NASDAQ:ATRA) Cut to Hold at RODMAN&RENSHAW - Defense World
Atara extends losses after FDA clinical hold - MSN
Clinical hold follows CRL for Atara - The Pharma Letter
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip - MSN
Atara Biotherapeutics stock hits 52-week low at $6.4 amid challenges - Investing.com
Atara, Already Slapped With CRL, Gets A Clinical Hold As Well - News & Insights
Stifel cuts Atara Biotherapeutics target to $5, holds rating By Investing.com - Investing.com UK
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs - AOL
US FDA puts clinical hold on Atara's trials for cancer cell therapies - Reuters
Atara stock extends losses on FDA clinical hold (ATRA:NASDAQ) - Seeking Alpha
Atara's New Drug Applications Placed on Hold by FDA - MarketWatch
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219 - Business Wire
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate - MSN
Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues - Seeking Alpha
Trend Tracker for (ATRA) - Stock Traders Daily
Canaccord Genuity Group Issues Pessimistic Forecast for Atara Biotherapeutics (NASDAQ:ATRA) Stock Price - Defense World
Atara stock plummets on FDA setback for EBV drug - MSN
Atara Bio reiterated at Buy by Canaccord on expected Ebvallo manufacture - Investing.com Canada
Atara In Disarray As Shares Sink On Ebvallo CRL - News & Insights
Atara down 41% on Ebvallo CRL - The Pharma Letter
Atara Biotherapeutics Provides Update on Review of Strategic Alternatives for CAR-T Assets - Marketscreener.com
US FDA declines to approve Atara Biotherapeutics' cancer therapy - MSN
Atara Biotherapeutics Shares Plunge 38% Following FDA Response t - GuruFocus.com
Atara sinks on Ebvallo CRL, seeks strategic alternatives - BioWorld Online
Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimates - Benzinga
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel) - Marketscreener.com
Stock market news: Atara Biotherapeutics -33.28%, Blaize Holdings -26.46% among biggest losers during mid day trading - Business Upturn
Manufacturing Issues Result in FDA Rejection of Atara’s Cell Therapy - BioSpace
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings - Benzinga
Atara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO Application - Yahoo Finance
Atara's allogeneic Epstein-Barr treatment hit with CRL - FirstWord Pharma
Atara Shares Sink After FDA Stalls Cancer Treatment - MarketWatch
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):